We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Allergy Therapeutics Plc | AGY | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 2.85 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.85 | 2.85 | 2.85 | 2.85 | 2.85 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 15/4/2024 08:40 by jimmyloser Good morning Farmer G.I am sorry but I feel the need to disagree. I believe that AGY have behaved professionally towards stakeholders and that news flow is where it should be.I am also in another share and if you were in there you would have cause to grumble. Not a peep for five months.Patience required here and in abundance.JL |
Posted at 12/4/2024 19:21 by jimmyloser Hi Farmer G.You know that this is AGY and that means that those of us who bought in for the ride need buckets of patience and the luck of the gods, I suspect a bit like sowing winter barley,I personally anticipate news this side of month end though I remain puzzled at the recent dramatic resignation by Mary T.Thoughts? |
Posted at 20/3/2024 22:10 by farmergeorge Are we optimistic about the outlook for AGY - been out of the loop for a while. |
Posted at 13/3/2024 12:31 by vergeltung Coinbase, Jimmy, I am as keen as any of you that AGY should finally escape its period of bad luck (partly caused by atrocious management - but that's a different matter, one Skygem surely must be asking themselves about) and notch up a few clinical achievements. I also agree that the news from the clinic has been good. However:1) I am underwhelmed at the reaction to the success of G306 announced in November (! 4 months ago!!)- which should occasion the start of final MA approvals and possibly of licensing / M&A activity; it raises questions about management competence that nothing seems afoot at all on this, a target the company has been aiming at since its foundation and 2) this recent Peanut announcement - extremely limited exposure with primarily safety objectives and some blood-chemistry. Highly promising though it is, it's all super-preliminary and represents the very start of the process that G306 supposedly represented the end of. I agree with you that there is great upside potential here but weighing on this are a) the issue of rudimentary management competence and b) the future financing needs which might turn out badly for us minor shareholders after resolutions 11-14 passed at the AGM. |
Posted at 12/3/2024 07:42 by coinbase Allergy Therapeutics commences subcutaneous dosing in peanut allergic patients in Phase I/IIa VLP Peanut PROTECT Trial - hXXps://www.londonst |
Posted at 14/2/2024 07:30 by coinbase Half-Year Trading Update - hXXps://www.londonst |
Posted at 29/12/2023 11:31 by vergeltung I have not read the details (not sure they will be public) but assuming all the important points to be covered in the press release, I am encouraged by this development.The new financing is best seen as part debt, part equity. AGY is not a good credit risk. Borrowing money at 12% is not expensive (you would not get a loan from an unconnected commercial lender on this interest alone). So the lending requires an equity 'kicker'. The warrants are worth little until the share price approaches 4p. Imagine selling call options on AGY equity with a strike price of 4p (i.e. about 60% out-of-the-money) - what would their price be? However, once the shares go over 4p the warrants boost the return on the lending. If the share price rises to 6p (more than 2x the current price), for example, the return to the lenders is 62% after 12 months. Greedy! But that is a big 'if'. Furthermore, if the warrants are issued they entitle the lenders to buy new shares at 4p - i.e. if all 1bn warrants are exercised the company receives a further £40m in cash. This funding like an optimistic move - much of the lenders' return depends upon the share price going up 60% from now (2.5p) and I am pleased that the insiders here appear to have confidence that this will happen. I do think this fundraise is good for the company and this seems to be the view of the market. |
Posted at 15/12/2023 16:44 by jimmyloser Holding shares in AGY is akin to playing snakes and ladders!impo. |
Posted at 14/11/2023 13:37 by jimmyloser Whilst this mornings RNS was appreciated, it was no great surprise to me.A 16% price increase is very welcome and the breakthrough by AGY a company currently based in Britain is nice to see. Both commercially and medically this is much needed news and I look forward to a continued flow of further upbeat news releases in the weeks ahead. As all know, I have remained optimistic, today was the first step in the right direction. CONGRATULATIONS TO ALL AT AGY ON THIS OUTSTANDING ACHIEVEMENT Potentially, what's next for us? Positive trial results imminently? - Achieved, thanks.✔ Consolidation? Progress on peanuts.? Successful fund raising? Expansion of markets? “This time next year, who knows”😊 Impo/dyor |
Posted at 10/8/2023 13:42 by 1kckeith This company has become some kind of corporate clown, blundering around the AIM stage in enormous comedic shoes, ‘accidentally&Our genius board and its advisors have managed to produce a situation where: 1. Investors are not investors. A major Insider Shareholder since years still does not have an Foreign Direct Investor (FDI) clearance. 2. The board is not in control (I). If this FDI approval is not forthcoming the Insider gets the company for nothing; who controls the process? (hint: the Insider! Actually it only needs use ‘reasonable endeavours’ re the FDI) 3. Good is Bad. If AGY too quickly achieves its biggest objective, striven for almost since the company’s foundation - a successful outcome for G306 - it is likely to be disastrous for shareholders. 4. More is less. If, against the odds, shareholders do get to subscribe in the largest fund-raise the company has ever had, AGY will still need more financing within months 5. The Board is not in control (II). AGY is in discussion with ‘certain shareholders’ (hint: the Insiders, SkyGem and Southern Fox) re financing after October. Hmm – who holds all the cards here? (hint: see previous hint) 6. Minus 20% is slight. Amazingly, even after last year’s cretinous shut-down, if AGY produces clinical trial material now it cannot make enough product for sale too, so projected sales will be ‘slightly lower’ than this year’s - which were short-supplied by the ‘short term pause in production’ aka the cretinous shut-down 7. The worthless is prioritised, the Important concealed. Fair value accounting: 33m warrants to buy shares at 30p is worthy of first mention (hint: it’s zero) but the known repayment premium on the Loan Facility comes second and is not quantified (hint: it’s huge at 250% and unaffordable). 8. Heads they win; tails, they don’t lose. The premium is payable if G306 is successful and the last FDI approval is not received by Jan 2024. Or if for any other reason the Equity Financing does not happen. Or if G306 is a failure. I could go on. Major worries are that October financing (what happens if it pre-dates the Equity Financing? What sort of punitive terms will the Insiders force down our throats when it does happen?) and the slim likelihood of the Open Offer actually happening. Like most clowns, this one is more terrifying than funny. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
